Clinical Trial

An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

Name: An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. — clinical trial record (NCT07598578)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.

Trial Details

NCT Number	NCT07598578
Lead Sponsor	Second Affiliated Hospital of Soochow University
Conditions	Peripheral T-Cell Lymphoma Refractory
Enrollment	30 participants
Start Date	2026-06-01
Primary Completion	2030-01-01 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-20